1-5 of 5
Jeremy Force
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer

Erika J. Crosby, Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Kay U. Wagner, William J. Muller, Lewis A. Chodosh, Gloria Broadwater, Terry Hyslop, Jonathan H. Shepherd, Daniel P. Hollern, Xiaping He, Charles M. Perou, Shengjie Chai, Benjamin K. Ashby, Benjamin G. Vincent, Joshua C. Snyder, Jeremy Force, Michael A. Morse, Herbert K. Lyerly, Zachary C. Hartman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4670–4681.
https://doi.org/10.1158/1078-0432.CCR-20-0389
Published: 01 September 2020
View article titled, Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Open the PDF for Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib

Ronan J. Kelly, Arun Rajan, Jeremy Force, Ariel Lopez-Chavez, Corrine Keen, Liang Cao, Yunkai Yu, Peter Choyke, Baris Turkbey, Mark Raffeld, Liqiang Xi, Seth M. Steinberg, John J. Wright, Shivaani Kummar, Martin Gutierrez, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (5): 1190–1199.
https://doi.org/10.1158/1078-0432.CCR-10-2331
Published: 01 March 2011
View article titled, Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib
Open the PDF for Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib in another window
Includes: Supplementary data
Journal Articles

Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

Geoffrey D. Girnun, Liang Chen, Jessica Silvaggi, Ronny Drapkin, Lucian R. Chirieac, Robert F. Padera, Rabi Upadhyay, Scott B. Vafai, Ralph Weissleder, Umar Mahmood, Elnaz Naseri, Stephanie Buckley, Danan Li, Jeremy Force, Kate McNamara, George Demetri, Bruce M. Spiegelman, Kwok-Kin Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6478–6486.
https://doi.org/10.1158/1078-0432.CCR-08-1128
Published: 16 October 2008
View article titled, Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin
Open the PDF for Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin in another window
Journal Articles

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

Anat Norden-Zfoni, Jayesh Desai, Judith Manola, Paul Beaudry, Jeremy Force, Robert Maki, Judah Folkman, Carlo Bello, Charles Baum, Sam E. DePrimo, David R. Shalinsky, Goerge D. Demetri, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (9): 2643–2650.
https://doi.org/10.1158/1078-0432.CCR-06-0919
Published: 01 May 2007
View article titled, Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
Open the PDF for Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor in another window
Journal Articles

Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity

Paul Beaudry, Jeremy Force, George N. Naumov, Andrew Wang, Cheryl H. Baker, Anderson Ryan, Shay Soker, Bruce E. Johnson, Judah Folkman, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3514–3522.
https://doi.org/10.1158/1078-0432.CCR-04-2271
Published: 02 May 2005
View article titled, Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity
Open the PDF for Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity in another window